Organigram Global Inc.
HealthcareNASDAQ:OGI · NASDAQ Global Select
-$0.02 today
Vol 0.25M · Avg 0.67M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-5.1%
avg -18.1%
ROIC
-9.3%
avg -15.8%
ROA
-3.2%
avg -15.0%
Analysis
ROA is currently the strongest return metric at -3.2% versus its period average of -15.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James H. Yamanaka | Chief Executive Officer & Director | $545,531.00 | — | 58 | — | — |
Timothy Emberg | President of Organigram Canada | $333,320.00 | — | — | — | — |
Greg Guyatt | Chief Financial Officer | $333,230.00 | — | — | — | — |
Helen Martin | Chief Legal Officer & Corporate Secretary | $331,730.00 | — | 48 | — | — |
Paolo De Luca | Chief Strategy Officer | $316,061.00 | — | 53 | — | — |
Peter L. Amirault | Executive Chairman | $68,109.00 | — | 65 | — | — |
Max Schwartz | Director of Investor Relations | — | — | — | — | — |
Megan Amber McCrae | Senior Vice President of Corporate Strategy & International Growth | — | — | — | — | — |
Nathalie Batten | Senior Vice President of Operations | — | — | — | — | — |
Valerie Rother | Chief People Officer | — | — | — | — | — |
Bradley Gunter | Senior Vice President of Sales | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +8.5% (14yr)1 analysts |
| Revenue | N/A | N/A | N/A | +36.9% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | +26.6% (14yr)1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +36.9% (14yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Electromed, Inc.
AMEX:ELMD
$307.52M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
$279.42M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Lifecore Biomedical, Inc.
NASDAQ:LFCR
$211.55M
Inventiva S.A.
NASDAQ:IVA
$200.13M
InfuSystem Holdings, Inc.
AMEX:INFU
$184.46M
Journey Medical Corporation
NASDAQ:DERM
$174.49M
Aurora Cannabis Inc.
NASDAQ:ACB
$172.40M
Solana Company
NASDAQ:HSDT
$89.92M
China SXT Pharmaceuticals, Inc.
SXTC
$1.99M
Who manages OGI?
Organigram Global Inc. (OGI) lists 11 active executives. The top listed executive is Max Schwartz, Director of Investor Relations.
Explore More
Continue the stock analysis
Jump to another research area for this company.